Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy by Citigroup

Citigroup upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a neutral rating to a buy rating in a report published on Tuesday, BenzingaRatingsTable reports.

NVO has been the subject of a number of other research reports. Barclays raised shares of Novo Nordisk A/S from an underweight rating to an equal weight rating and set a $51.85 price target for the company in a report on Tuesday, June 11th. Pareto Securities raised shares of Novo Nordisk A/S from a hold rating to a buy rating in a report on Monday, August 5th. UBS Group reaffirmed a buy rating and issued a $355.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. ValuEngine downgraded shares of Novo Nordisk A/S from a hold rating to a sell rating in a report on Tuesday, September 10th. Finally, Jefferies Financial Group downgraded shares of Novo Nordisk A/S from a hold rating to an underperform rating in a report on Friday, August 30th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $159.65.

Shares of NYSE:NVO opened at $52.94 on Tuesday. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $53.55. The company has a 50-day moving average price of $51.10 and a 200 day moving average price of $49.98. The company has a market cap of $125.36 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 2.15 and a beta of 0.57.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Friday, August 9th. The company reported $0.61 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.61. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. The firm had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.41 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 2.43 EPS for the current year.

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, August 27th. Investors of record on Monday, August 19th were given a $0.318 dividend. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 25.40%.

Institutional investors have recently bought and sold shares of the stock. Clearbridge Investments LLC raised its position in Novo Nordisk A/S by 42.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after purchasing an additional 344,989 shares during the period. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 89.5% during the second quarter. Jennison Associates LLC now owns 1,229,986 shares of the company’s stock worth $62,778,000 after acquiring an additional 580,944 shares during the period. AE Wealth Management LLC purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $283,000. Mirova purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $49,000. Finally, GYL Financial Synergies LLC purchased a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $1,090,000. 7.34% of the stock is currently owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: High-Yield Dividend Stocks

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.